225 related articles for article (PubMed ID: 10320627)
1. Preemptive pharmacologic intervention in radiation-induced salivary dysfunction.
Taylor SE; Miller EG
Proc Soc Exp Biol Med; 1999 May; 221(1):14-26. PubMed ID: 10320627
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology and management of radiation-induced xerostomia.
Berk LB; Shivnani AT; Small W
J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
4. Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists.
Coppes RP; Zeilstra LJ; Kampinga HH; Konings AW
Br J Cancer; 2001 Sep; 85(7):1055-63. PubMed ID: 11592779
[TBL] [Abstract][Full Text] [Related]
5. New approaches to preventing xerostomia.
J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
[No Abstract] [Full Text] [Related]
6. Salivary gland sparing in the treatment of head and neck cancer.
Scrimger R
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1437-48. PubMed ID: 21929317
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.
Vissink A; Mitchell JB; Baum BJ; Limesand KH; Jensen SB; Fox PC; Elting LS; Langendijk JA; Coppes RP; Reyland ME
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):983-91. PubMed ID: 20970030
[TBL] [Abstract][Full Text] [Related]
8. Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment.
Guchelaar HJ; Vermes A; Meerwaldt JH
Support Care Cancer; 1997 Jul; 5(4):281-8. PubMed ID: 9257424
[TBL] [Abstract][Full Text] [Related]
9. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
de Castro G; Federico MH
Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
[TBL] [Abstract][Full Text] [Related]
10. Natural history and prevention of radiation injury.
O'Connell AC
Adv Dent Res; 2000 Dec; 14():57-61. PubMed ID: 11842925
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy-induced salivary dysfunction.
Ship JA; Hu K
Semin Oncol; 2004 Dec; 31(6 Suppl 18):29-36. PubMed ID: 15726520
[TBL] [Abstract][Full Text] [Related]
12. Radiation-induced xerostomia in patients with head and neck cancer: a literature review.
Dirix P; Nuyts S; Van den Bogaert W
Cancer; 2006 Dec; 107(11):2525-34. PubMed ID: 17078052
[TBL] [Abstract][Full Text] [Related]
13. Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth).
Malallah OS; Garcia CMA; Proctor GB; Forbes B; Royall PG
Int J Pharm; 2018 Apr; 541(1-2):157-166. PubMed ID: 29425763
[TBL] [Abstract][Full Text] [Related]
14. Systemic pilocarpine for treatment of xerostomia.
Berk L
Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1333-40. PubMed ID: 18798702
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 clinical study of cell therapy with effective-mononuclear cells (E-MNC) for radiogenic xerostomia (first-in-human study) (FIH study on E-MNC therapy for radiogenic xerostomia).
Sumita Y; Iwamoto N; Seki M; Yoshida T; Honma R; Iwatake M; Ohba S; Takashi I; Hotokezaka Y; Harada H; Kuroshima S; Nagai K; Asahara T; Atsushi Kawakam I; Asahina I
Medicine (Baltimore); 2020 Jun; 99(26):e20788. PubMed ID: 32590759
[TBL] [Abstract][Full Text] [Related]
16. Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy.
Garg AK; Malo M
J Am Dent Assoc; 1997 Aug; 128(8):1128-33. PubMed ID: 9260423
[TBL] [Abstract][Full Text] [Related]
17. The use of oral pilocarpine in xerostomia and Sjögren's syndrome.
Nusair S; Rubinow A
Semin Arthritis Rheum; 1999 Jun; 28(6):360-7. PubMed ID: 10406404
[TBL] [Abstract][Full Text] [Related]
18. [Current status of prevention and management of radiation-induced xerostomia].
Ma DY; Qiu WL; Zhang CP
Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
[No Abstract] [Full Text] [Related]
19. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
Chao KS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
Thorstad WL; Haughey B; Chao KS
Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
